| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effects on the heart and other vascular tissues
1 CIHR Group on Molecular and Cell Biology, Departments of Medicine & Biochemistry, University of Alberta, Edmonton, AB, Canada
2 Institut de Genetique et Biologie Moleculaire et Cellulaire, Illkirch, France
* To whom correspondence should be addressed. E-mail: gordon.francis{at}ualberta.ca.
Peroxisome proliferator-activated receptor alpha (PPAR
) is a member of the large nuclear receptor superfamily whose main role is to activate genes involved in fatty acid oxidation in the liver, heart, kidney and skeletal muscle. While currently used mainly as hypolipidemic agents, the cardiac effects and anti-inflammatory actions of PPAR agonists in arterial wall cells suggest other potential cardioprotective and anti-atherosclerotic effects of these agents. This review summarizes current knowledge regarding the effects of PPAR agonists on lipid and lipoprotein metabolism, the heart, and the vessel wall, and introduces some of the insights gained in these areas from studying PPAR-deficient mice. The introduction of new and more potent PPAR agonists will provide important insights into the overall benefits of activating PPAR clinically for the treatment of dyslipidemia and prevention of vascular disease.
This article has been cited by other articles:
|
|
 |
|
  K. M. Tordjman, C. F. Semenkovich, T. Coleman, R. Yudovich, S. Bak, E. Osher, M. Vechoropoulos, and N. Stern Absence of Peroxisome Proliferator-Activated Receptor-{alpha} Abolishes Hypertension and Attenuates Atherosclerosis in the Tsukuba Hypertensive Mouse Hypertension, November 1, 2007; 50(5): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schulz and M. A. M. Ali PPAR{alpha}: essential component to prevent myocardial oxidative stress? Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H11 - H12. [Full Text] [PDF]
|
|
|
|
|
|
T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Park, H. W. Kim, S. H. Ko, J. H. Lim, G. R. Ryu, H. W. Chung, S. W. Han, S. J. Shin, B. K. Bang, M. D. Breyer, et al. Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1227 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Park, H. W. Kim, S. H. Ko, H. W. Chung, S. W. Lim, C. W. Yang, Y. S. Chang, A. Sugawara, Y. Guan, and M. D. Breyer Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator-Activated Receptor {alpha}. Diabetes, April 1, 2006; 55(4): 885 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
